Sales of first big COVID-19 drug, remdesivir, may disappoint
LONDON: Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc. reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first ...
from Google Alert - Business https://ift.tt/3nVDEzU
LONDON: Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc. reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first ... https://ift.tt/eA8V8J
from Google Alert - Business https://ift.tt/3nVDEzU
LONDON: Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc. reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first ... https://ift.tt/eA8V8J
Comments
Post a Comment